Trial Profile

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms PREDICT
Sponsors Bayer

Most Recent Events

19 Oct 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004113).
13 Sep 2011 Final results will be presented at ECCO-ESMO 2011, according to a Bayer press release.
29 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com